Susan T Paulukonis1, Lisa B Feuchtbaum2, Thomas D Coates3, Lynne D Neumayr4, Marsha J Treadwell4, Elliott P Vichinsky4, Mary M Hulihan5. 1. California Rare Disease Surveillance Program, Public Health Institute, Richmond, California. 2. Genetic Disease Screening Program, California Department of Public Health, Richmond, California. 3. Children's Center for Cancer and Blood Diseases, Children's Hospital of Los Angeles, Los Angeles, California. 4. Division of Hematology/Oncology, University of California San Francisco Benioff Children's Hospital Oakland, Oakland, California. 5. Division of Blood Disorders, Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
BACKGROUND: Clinical care for children and adults living with sickle cell disease (SCD) is often provided in the emergency department (ED). Population-based surveillance data can be used to describe the ED utilization patterns of this patient population. PROCEDURE: A cohort of pediatric and adult California patients with SCD was identified from multiple data sources, and 10 years (2005-2014) of their treat-and-release ED utilization data were analyzed. RESULTS: Among a cohort of 4,636 patients with SCD, 4,100 (88%) had one or more treat-and-release ED visits. There were 2.1 mean annual visits per person for the cohort (median 0.7; range 0-185). In a single year (2005), 53% had 0 treat-and-release ED visits, 35% had 1-3 visits, 9% had 4-10 visits, and 3% had 11 or more visits; this highest utilization group accounted for 45% of all patients' ED visits. ED utilization in this cohort was highest among young adults and also higher among older adults than pediatric patients. CONCLUSION: The majority of identified patients in each of the 10 years did not go to the ED, but nearly all had one or more such visits over the full span of time. This study highlights the power and utility of a multisource longitudinal data collection effort for SCD. Further study of the segment of the population with highest ED utilization may highlight areas where changes in healthcare and health policy could improve and extend the lives of patients with SCD.
BACKGROUND: Clinical care for children and adults living with sickle cell disease (SCD) is often provided in the emergency department (ED). Population-based surveillance data can be used to describe the ED utilization patterns of this patient population. PROCEDURE: A cohort of pediatric and adult Californiapatients with SCD was identified from multiple data sources, and 10 years (2005-2014) of their treat-and-release ED utilization data were analyzed. RESULTS: Among a cohort of 4,636 patients with SCD, 4,100 (88%) had one or more treat-and-release ED visits. There were 2.1 mean annual visits per person for the cohort (median 0.7; range 0-185). In a single year (2005), 53% had 0 treat-and-release ED visits, 35% had 1-3 visits, 9% had 4-10 visits, and 3% had 11 or more visits; this highest utilization group accounted for 45% of all patients' ED visits. ED utilization in this cohort was highest among young adults and also higher among older adults than pediatric patients. CONCLUSION: The majority of identified patients in each of the 10 years did not go to the ED, but nearly all had one or more such visits over the full span of time. This study highlights the power and utility of a multisource longitudinal data collection effort for SCD. Further study of the segment of the population with highest ED utilization may highlight areas where changes in healthcare and health policy could improve and extend the lives of patients with SCD.
Authors: Hussain R Yusuf; Hani K Atrash; Scott D Grosse; Christopher S Parker; Althea M Grant Journal: Am J Prev Med Date: 2010-04 Impact factor: 5.043
Authors: Mercy Mvundura; Djesika Amendah; Patricia L Kavanagh; Philippa G Sprinz; Scott D Grosse Journal: Pediatr Blood Cancer Date: 2009-10 Impact factor: 3.167
Authors: Mark Nimmer; Raymond G Hoffmann; Mahua Dasgupta; Julie Panepinto; David C Brousseau Journal: J Pediatr Hematol Oncol Date: 2015-01 Impact factor: 1.289
Authors: Susan Claster; Amanda Termuhlen; Sheree M Schrager; Julie A Wolfson; Ellen Iverson Journal: Pediatr Blood Cancer Date: 2013-08-26 Impact factor: 3.167
Authors: Mariam Kayle; Jhaqueline Valle; Susan Paulukonis; Jane L Holl; Paula Tanabe; Dustin D French; Ravi Garg; Robert I Liem; Sherif M Badawy; Marsha J Treadwell Journal: Pediatr Blood Cancer Date: 2020-03-08 Impact factor: 3.167
Authors: Alon Peltz; Margaret E Samuels-Kalow; Jonathan Rodean; Matthew Hall; Elizabeth R Alpern; Paul L Aronson; Jay G Berry; Kathy N Shaw; Rustin B Morse; Stephen B Freedman; Eyal Cohen; Harold K Simon; Samir S Shah; Yiannis Katsogridakis; Mark I Neuman Journal: Pediatrics Date: 2017-08-01 Impact factor: 7.124
Authors: Kimberly S Esham; Angie Mae Rodday; Hedy P Smith; Farzad Noubary; Ruth Ann Weidner; Rachel J Buchsbaum; Susan K Parsons Journal: Blood Adv Date: 2020-01-14
Authors: Deborah Lubeck; Irene Agodoa; Nickhill Bhakta; Mark Danese; Kartik Pappu; Robin Howard; Michelle Gleeson; Marc Halperin; Sophie Lanzkron Journal: JAMA Netw Open Date: 2019-11-01